Investor Update

Basel, 15 October 2018

Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 2018

Dear Investor,

Please find attached a press release by Chugai.

Do not hesitate to contact us for any further questions.